5 Killed In Blaze At Serum Institute Of India
Jan 21, 2021 | Pratirodh Bureau
Employees leave as smoke rises from a fire at the Serum Institute of India, the world's largest vaccine maker, that is manufacturing the AstraZeneca/Oxford University vaccine for the coronavirus, in Pune on January 21, 2021. (AP Photo/Rafiq Maqbool)
At least five people were killed in a fire that broke out on Thursday at a building under construction at Serum Institute of India, the world’s largest vaccine manufacturer, officials said. The company said the blaze would not affect production of the COVID-19 vaccine.
Murlidhar Mohol, mayor of Pune city, said five bodies were found in the rubble after the flames were extinguished by firefighters.
Mahol said the victims were probably construction workers. He said the cause of the fire had not been determined and the extent of damage was not immediately clear.
Serum Institue of India’s CEO, Adar Poonwala, said he was “deeply saddened” by the loss of life.
He said there would be no reduction in vaccine manufacturing because the company has other available facilities.
The company said the fire was restricted to a new facility it is constructing to increase the production of COVID-19 vaccines and ensure it is better prepared for future pandemics.
It said the fire did not affect existing facilities making COVID-19 vaccines or a stockpile of around 50 million doses.
Images showed huge plumes of smoke billowing from the building as firefighters worked to extinguish the blaze. Dozens of company workers in lab suits left the compound.
Serum Institute of India is the world’s largest maker of vaccines and has been contracted to manufacture a billion doses of the AstraZeneca/Oxford University vaccine.
Poonawalla said in an interview with The Associated Press last month that it hopes to increase production capacity from 1.5 billion doses to 2.5 billion doses per year by the end of 2021. The new facility is part of the expansion.
Of the more than 12 billion coronavirus vaccine doses expected to be produced this year, rich countries have already bought about 9 billion, and many have options to buy even more. As a result, Serum Institute is likely to make most of the vaccines that will be used by developing nations.